Donna Haney, MD
Family Medicine · Zebulon, GANPI 1497821862
Payments from drug & device makers
Across 39 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$87
- Novo Nordisk$79
- Biohaven Pharmaceuticals, Inc.$78
- Pfizer$61
- Bayer$55
- AbbVie$55
- plus $338 from 11 others
What the payments were for
- Food & beverage$752100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 4 | $87 |
| Novo Nordisk | 5 | $79 |
| Biohaven Pharmaceuticals, Inc. | 3 | $78 |
| Pfizer | 3 | $61 |
| Bayer | 3 | $55 |
| AbbVie | 3 | $55 |
| Boehringer Ingelheim | 2 | $47 |
| Amgen | 3 | $46 |
| AstraZeneca | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $45 |
| Exact Sciences | 2 | $32 |
| GSK | 2 | $28 |
| Amarin Pharma, Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Nalpropion Pharmaceuticals LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $15 |
How this compares
$752 in reported general payments places this provider in the 55th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $984 |
| Atorvastatin Calcium | 72 | $937 |
| Losartan Potassium | 39 | $549 |
| Rosuvastatin Calcium | 14 | $356 |
| Memantine Hcl | 13 | $321 |
| Amlodipine Besylate | 60 | $293 |
| Duloxetine Hcl | 13 | $274 |
| Flecainide Acetate | 12 | $262 |
| Gabapentin | 15 | $259 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $259 |
| Levothyroxine Sodium | 20 | $200 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 12 | $171 |
| Pantoprazole Sodium | 17 | $163 |
| Fluticasone Propionate | 17 | $136 |
| Lisinopril | 19 | $131 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Zebulon
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.